Pyrrolidine aryl-ether as NK-3 receptor antagonists

The compound of formula I, wherein

• Ar1 is pyridinyl;
• Ar2 is pyridinyl;
• R1 is hydrogen, halogen, lower alkyl, lower alkoxy, cyano, amino, mono or di-lower alkyl amino, cycloalkyl or is lower alkyl substituted by halogen, cyano or amino;
• R2 is hydrogen, halogen, lower alkyl, cyano or is lower alkyl substituted by halogen or cyano;
• R3 is hydrogen or lower alkyl;
• R4 is hydrogen, lower alkyl or halogen;
• n is 1, 2 or 3;
• in case n is 2 or 3, each R1 is the same or different;
• o is 1, 2 or 3;
• in case o is 2 or 3, each R2 is the same or different;
• and
• p is 1, 2 or 3;
• in case p is 2 or 3, each R4 is the same or different;
• or to a pharmaceutically active salt thereof.

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• Ar1 is pyridinyl;
• Ar2 is pyridinyl;
• R1 is hydrogen,
• halogen,
• lower alkyl,
• lower alkoxy,
• lower alkyl substituted by halogen,
• lower alkoxy substituted by halogen,
• S-lower alkyl,
• —S(O)2-lower alkyl,
• —S(O)2-di-lower alkyl amino,
• —(CH2)qR,
• cyano,
• amino,
• mono or di-lower alkyl amino,
• NHC(O)-lower alkyl, or
• cycloalkyl
• wherein R is cyano, di-lower alkyl amino or pyrrolidin-1-yl;
• R2 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano;
• R3 is hydrogen or lower alkyl or CH2OH;
• R4 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano;
• n is 1, 2 or 3;
• in case n is 2 or 3, each R1 is the same or different;
• o is 1, 2 or 3;
• in case o is 2 or 3, each R2 is the same or different;
• p is 1, 2 or 3;
• in case p is 2 or 3, each R4 is the same or different;
• and
• q is 1 or 2;
• or a pharmaceutically active salt thereof, diastereoisomer enantiomer or racemic or non-racemic mixture thereof and a pharmaceutically acceptable carrier.